CN105130997A - 一种库潘尼西的制备方法 - Google Patents

一种库潘尼西的制备方法 Download PDF

Info

Publication number
CN105130997A
CN105130997A CN201510617987.6A CN201510617987A CN105130997A CN 105130997 A CN105130997 A CN 105130997A CN 201510617987 A CN201510617987 A CN 201510617987A CN 105130997 A CN105130997 A CN 105130997A
Authority
CN
China
Prior art keywords
preparation
pannixi
base
morpholine
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510617987.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105130997B (zh
Inventor
许学农
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tongling wangyantang Biotechnology Co., Ltd
Original Assignee
Suzhou Miracpharma Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Miracpharma Technology Co Ltd filed Critical Suzhou Miracpharma Technology Co Ltd
Priority to CN201510617987.6A priority Critical patent/CN105130997B/zh
Publication of CN105130997A publication Critical patent/CN105130997A/zh
Application granted granted Critical
Publication of CN105130997B publication Critical patent/CN105130997B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
CN201510617987.6A 2015-09-25 2015-09-25 一种库潘尼西的制备方法 Active CN105130997B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510617987.6A CN105130997B (zh) 2015-09-25 2015-09-25 一种库潘尼西的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510617987.6A CN105130997B (zh) 2015-09-25 2015-09-25 一种库潘尼西的制备方法

Publications (2)

Publication Number Publication Date
CN105130997A true CN105130997A (zh) 2015-12-09
CN105130997B CN105130997B (zh) 2017-12-05

Family

ID=54716624

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510617987.6A Active CN105130997B (zh) 2015-09-25 2015-09-25 一种库潘尼西的制备方法

Country Status (1)

Country Link
CN (1) CN105130997B (und)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法
CN108884496A (zh) * 2016-02-01 2018-11-23 拜耳制药股份公司 Copanlisib生物标志物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯－嘧啶衍生物
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯－嘧啶衍生物
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. BALAKUMAR，等: "Synthesis, anti-in flammatory evaluation and docking studies of some new fluorinated fused quinazolines", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *
CESAR MENDOZA-MARTÍNEZ，等: "Antileishmanial activity of quinazolin e derivatives: Synthesis, docking screens, molecular dynamic simulations and electrochemical studies", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法
CN108884496A (zh) * 2016-02-01 2018-11-23 拜耳制药股份公司 Copanlisib生物标志物

Also Published As

Publication number Publication date
CN105130997B (zh) 2017-12-05

Similar Documents

Publication Publication Date Title
AU2018365174B2 (en) Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
ES2794639T3 (es) Forma cristalina, método de preparación y compuesto intermedio de compuesto con anillo dihidropirido
ES2618007T3 (es) Nuevos compuestos de pirrolopirimidina como inhibidores de proteína cinasas
AU2021261879A1 (en) Synthesis of N-(heteroaryl)-pyrrolo[2,3-d]pyrimidin-2-amines
EP2949647A1 (en) Deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing same
JP5735659B2 (ja) シタグリプチンの中間体の製造方法
ES2879294T3 (es) Formas polimórficas de Belinostat y procesos para la preparación de las mismas
ES2593059T3 (es) Compuestos para el tratamiento y profilaxis de enfermedad por virus sincitial respiratorio
ES2552166T3 (es) Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas
CN105130997A (zh) 一种库潘尼西的制备方法
CN112279838B (zh) 一种吡咯替尼的制备方法
CN105712919B (zh) 酰胺缩合剂在维格列汀合成方法中的应用
CA3129936A1 (en) Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one
ES2759795T3 (es) Nuevo método para la preparación de un compuesto de tienopirimidina e intermedios usados en el mismo
CN105130998A (zh) 库潘尼西的制备方法
WO2016061718A1 (zh) 一种化合物及其制备方法以及美登素dm1的制备方法
EP3275882B1 (en) Process of synthesizing substituted pyridine and pyrimidine compound
CN104725292A (zh) 一种(s)(-)-氨磺必利的制备方法
CN111747949B (zh) Bcl-2选择性抑制剂的制备方法
CN105985317A (zh) 一种色瑞替尼的制备方法及其中间体
KR20230117416A (ko) 아미노피리미딘계 fak 억제제 화합물의 합성 방법
CN103083313A (zh) 一种取代吡咯色原酮类化合物在制备治疗5型磷酸二酯酶相关疾病的药物中的应用
CN111196782B (zh) 二氢化氮杂萘类化合物、其制备方法及用途
CN106187886B (zh) 一种制备高纯度伯舒替尼一水合物的方法
CN116693533A (zh) 一种五元杂芳环类menin-MLL相互作用抑制剂、其制备方法及医药用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20201010

Address after: No.21, Yangwan street, Yijin Town, Zongyang County, Tongling City, Anhui Province

Patentee after: Tongling wangyantang Biotechnology Co., Ltd

Address before: 215000 Jiangsu Province, Suzhou City Industrial Park Commercial Plaza Building 1 room 1305 Lianfeng

Patentee before: SUZHOU MIRACPHARMA TECHNOLOGY Co.,Ltd.